Baicalin mitigates cognitive impairment and protects neurons from microglia-mediated neuroinflammation via suppressing NLRP3 inflammasomes and TLR4/NF-κB signaling pathway.

Jin X, Liu MY, Zhang DF, Zhong X, Du K, Qian P, Yao WF, Gao H, Wei MJ. · 2019

Read Baicalin mitigates cognitive impairment and protects neurons from microglia-mediated neuroinflammation via suppressing NLRP3 inflammasomes and TLR4/NF-κB signaling pathway. by Jin X, Liu MY, Zhang DF, Zhong X, Du K, Qian P, Yao WF, Gao H, Wei MJ. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6488900.txt.

Introduction

Jin and co-authors test baicalin, a flavonoid from the root of Scutellaria baicalensis, against Alzheimer's-style brain inflammation in APP/PS1 mice and microglia grown in dishes. Pretreated mice kept their spatial memory in the water maze and passive avoidance tests far better than untreated controls.

Baicalin quieted microglia, cut alarm protein output, and spared neurons from inflammation-driven cell death, all without reducing amyloid buildup itself. The mechanism: it suppressed assembly of the NLRP3 inflammasome and signaling through TLR4 and NF-κB, in brain tissue and in BV2 cells provoked with the toxin LPS and amyloid. The compound stands as a candidate to protect the brain by aiming at the inflammatory half of the disease.

Catalog record

CREATORJin X, Liu MY, Zhang DF, Zhong X, Du K, Qian P, Yao WF, Gao H, Wei MJ.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE62 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6488900

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Baicalin mitigates cognitive impairment and protects neurons from microglia‐mediated neuroinflammation via suppressing NLRP3 inflammasomes and TLR4/NF‐κB signaling pathway By Xin Jin, Ming‐Yan Liu, Dong‐Fang Zhang, Xin Zhong, Ke Du, Ping Qian, Wei‐Fan Yao, Hua Gao, Min‐Jie Wei Published in: CNS Neuroscience & Therapeutics DOI: 10.1111/cns.13086 ABSTRACT Summary Aims Baicalin (BAI), a flavonoid compound isolated from the root of Scutellaria baicalensis Georgi, has been established to have potent anti‐inflammation and neuroprotective properties; however, its effects during Alzheimer's disease (AD) treatment have not been well studied. This study aimed to investigate the effects of BAI pretreatment on cognitive impairment and neuronal protection against microglia‐induced neuroinflammation and to explore the mechanisms underlying its anti‐inflammation effects. Methods To determine whether BAI plays a positive role in ameliorating the memory and cognition deficits in APP (amyloid beta precursor protein)/PS1 (presenilin‐1) mice, behavioral experiments were conducted. We assessed the effects of BAI on microglial activation, the production of proinflammatory cytokines, and neuroinflammation‐mediated neuron apoptosis in vivo and in vitro using Western blot, RT‐PCR, ELISA, immunohistochemistry, and immunofluorescence. Finally, to elucidate the anti‐inflammation mechanisms underlying the effects of BAI, the protein expression of NLRP3 inflammasomes and the expression of proteins involved in the TLR4/NF‐κB signaling pathway were measured using Western blot and immunofluorescence. Results The results indicated that BAI treatment attenuated spatial memory dysfunction in APP/PS1 mice, as assessed by the passive avoidance test and the Morris water maze test. Additionally, BAI administration effectively decreased the number of activated microglia and proinflammatory cytokines, as well as neuroinflammation‐mediated neuron apoptosis, in APP/PS1 mice and LPS (lipopolysaccharides)/Aβ‐stimulated BV2 microglial cells. Lastly, the molecular mechanistic study revealed that BAI inhibited microglia‐induced neuroinflammation via suppression of the activation of NLRP3 inflammasomes and the TLR4/NF‐κB signaling pathway. Conclusion Overall, the results of the present study indicated that BAI is a promising neuroprotective compound for use in the prevention and treatment of microglia‐mediated neuroinflammation during AD progression. Keywords: Alzheimer's disease, baicalin, cognitive impairment, neuroinflammation, neuronal protection INTRODUCTION Neuroinflammation is closely related to neuronal apoptosis during the progression of Alzheimer's disease (AD).1 The pathological hallmarks of neuroinflammation seen in AD are due to the presence of activated microglia within β‐amyloid (Aβ) deposits.2 Microglial cells, the resident macrophages in the CNS parenchyma, play an important role in neuroinflammatory and immune responses.3 They serve as the first line of defense in the brain and protect the CNS from insults. Microglial cells are promptly activated in response to a variety of stimuli, including infectious, pathological stimuli or Aβ peptide. Activated microglia are able to secrete vast amounts of proinflammatory cytokines, such as tumor necrosis factor (TNF)‐α and interleukin (IL)‐1β, which generate neuroinflammation and cause neuronal apoptosis or death, eventually resulting in the behavioral and psychological symptoms of AD.4, 5 Therefore, based on the neuropathological features of the AD etiology, the inhibition of microglial activation and the protection of neurons from neuroinflammation may be an alternative strategy that could be used for the treatment of AD. Currently, the accumulated epidemiological evidence has demonstrated that conventional nonsteroidal anti‐inflammation drug (NSAID) therapies are, to a certain extent, able to reduce neuroinflammatory responses, delay AD progression, and reduce the severity of cognitive impairment.6 Regrettably, the incidence of gastrointestinal complications limits the long‐term clinical use of NSAIDs for primary treatment of AD.7 Consequently, the development of a drug with either limited or no side effects that can inhibit microglial activation and neuroinflammation has become necessary for the treatment of AD. Interestingly, natural products with fewer side effects and safer properties have been widely consumed or used as therapeutic agents by human societies for many centuries.8 Recently, several studies have reported that a great number of natural products and their derivatives have been developed into new or already approved drugs for the treatment of diseases that play a vital role in supporting drug discovery and development.9 Moreover, natural products have been shown to have valuable effects during the treatment of microglia‐mediated neuroinflammation in numerous studies.10, 11 Therefore, they can be considered as an alternative strategy that can be used in the discovery of potential therapeutic drugs for treating AD. Baicalin (BAI), a flavonoid compound, is responsible for most of the biological effects of Scutellaria baicalensis, which has been traditionally used as an herbal medicine in China for many centuries to treat various inflammatory diseases. The anti‐inflammation potential of BAI has been observed in many modern experimental models of both peripheral and central inflammation.12, 13 Recently, the available evidence has suggested that BAI may exert neuroprotective effects in neurodegenerative disease‐related models. Studies have shown that BAI inhibited apoptosis of Aβ‐induced SH‐SY5Y cells, attenuated oxygen‐glucose deprivation–induced microglial activation, and improved chronic corticosterone‐induced cognitive impairment.14, 15, 16 In addition, BAI also reversed impairment of synaptogenesis and memory deficits in rats affected by minimal hepatic encephalopathy (MHE).17 These findings indicated that BAI may represent a promising candidate that could be used for neurodegeneration treatment and reduction of the risk of AD. However, it is unknown whether BAI beneficially affects cognitive function and attenuates inflammatory reactions in APP/PS1 mice. Therefore, the goal of this study was to evaluate the effect of chronic BAI administration on behavior/cognition, microglial activation, neuronal apoptosis, and neuroinflammatory responses, as well as potential anti‐inflammation mechanisms, in both APP/PS1 mice and LPS/Aβ‐induced BV2 cells. MATERIALS AND METHODS Chemicals 2.1. BAI (95% purity; Aladdin Chemicals Ltd., Shanghai, China) was suspended in 0.3% sodium carboxyl methyl cellulose (CMC‐Na) aqueous solution at a concentration of 10.3 mg/mL. Aβ1‐42 (Sigma‐Aldrich, St. Louis, USA) was diluted in sterile PBS at a final concentration of 1 mg/mL. The solution was then allowed to aggregate for 7 days at 37°C. Cell culture 2.2. The immortalized murine microglial cell line BV2 and human neuroblastoma SH‐SY5Y cells were purchased from the Chinese Academy of Medical Sciences (Beijing, China). BV2 cells were cultured in high‐glucose DMEM containing 5% fetal bovine serum (HyClone Inc., UT, USA) at 37°C with 5% CO2, and 100 U/mL of penicillin/streptomycin. SH‐SY5Y cells were cultured in DMEM/F‐12 containing with 10% fetal bovine serum (HyClone Inc) at 37°C with 5% CO2, and 100 U/mL of penicillin/streptomycin. CCK‐8 cell viability assay 2.3. The cell viability was measured using CCK‐8 kit according to the manufacturer's instructions (Dojindo, Kumamoto, Japan). Briefly, BV2 cells were plated in 96‐well plates at a density of 4 × 103 cells/well. Subsequently, the cells were treated with different concentrations of BAI (0, 10, 20, and 40 μmol/L) for 72 hours. The cells were pretreated with different concentrations of BAI (0, 10, 20, and 40 μmol/L) for 1 hour followed by the stimulation with 10 μmol/L Aβ1‐42 and 1 μg/mL LPS for 24 hours. After incubation, the CCK‐8 solution (10 μL/well) was added to each well. Then, the cells were incubated for 3 hours at 37°C. The optical density was determined at 450 nm using a microplate spectrophotometer (Multiskan FC; Thermo Fisher Scientific Inc., MA, USA). The cell viability was expressed as the percentage of Abs 450 nm of vehicle control. All assays were performed in triplicate. Microglia‐conditioned media system 2.4. A microglia‐conditioned media system was used as previously described.18 BV2 cells were plated in 6‐well culture plates at a density of 2 × 105 cells/well. After overnight incubation, the cells were pretreated with different concentrations of BAI for 1 hour

Read the complete text